The researchers noted that confirmation of these results are needed through large, multicenter cohort studies, particularly with regard to how allergic asthma might have a protective effect against SARS-CoV-2 infection. “I think going forward, these findings are very interesting and need to be looked at further to explain the mechanism behind them better,” Dr. Eggert said.
“I think there is also a lot of interest in how this might affect our patients on biologics, which deplete the eosinophils and get rid of that allergic phenotype,” she added. “Does that have any effect on disease severity? Unfortunately, the number of patents on biologics was very small in our cohort, but I do think this is an interesting area for exploration.”
This study was funded in part by the Sean N. Parker Center for Allergy & Asthma Research, Stanford University, Sunshine Foundation, Crown Foundation, and the Parker Foundation.